Pandemic Likely Reduced Access to Parkinson’s Medication Globally, Hit Poorer Countries Harder

Pandemic Likely Reduced Access to Parkinson’s Medication Globally, Hit Poorer Countries Harder
5
(1)

The COVID-19 pandemic likely limited access to Parkinson’s disease medication globally, causing a worsening of patients’ symptoms, according to a recent study.

Also, poorer countries appear to have been affected more than wealthier ones, according to the study, “The impact of COVID‐19 on access to Parkinson’s disease medication,” which was published in the journal Movement Disorders.

An international team of researchers assessed the pandemic’s impact on access to Parkinson’s medications by sending a 14-question survey to the roughly 10,000 members on the Movement Disorders Society email list.

The survey was sent June 4 and again on June 23. As of July 8, 346 responses had been analyzed.

Of those responses, 317 (nearly 92%) came from doctors, with India (9.2%), Brazil (7.5%), and the United States (6.1%) accounting for the greatest number of respondents.

Overall, more than 45% of respondents (157 patients) reported their patients had experienced difficulty obtaining their Parkinson’s medication as a result of the pandemic.

Of those, 134 (59%) reported increased disability, 19 (8.4%) reported increased hospitalization, six (2.6%) reported increased mortality and 68 (30%) felt that the COVID-19 pandemic had no obvious clinical impact on people with Parkinson’s.

At least half of the respondents from eight of the 16 regions included in the study reported difficulty in maintaining regular access to Parkinson’s medication throughout the pandemic.

Text responses from Kenya, Bangladesh, Ghana, and the U.S. described reductions in medication availability for reasons such as transportation disruptions, lower economic development, and both individual and systemic financial challenges.

The impact that COVID-19 had on access to medication varied with countries’ income.

Of those respondents who reported such difficulty, nearly 88% came from low-, 64% from low-middle, 57.6% from upper-middle, and nearly 23% from high-income countries.

As a country’s income level declined, the increase in reported disability rose, from 37.2% among high-income countries to 100% among low-income countries.

The researchers noted that lockdowns, implemented by many countries in an attempt to control the spread of the virus, and the diversion of resources toward pandemic responses may have caused considerable disruptions to delivery systems, clinical procedures, and access to dispensaries.

Although telemedicine has surged in use, the researchers mentioned that it may be more valuable for follow-up treatment than for initial assessments and diagnoses. Furthermore, patients who struggle with cognitive impairments, impulse control, and psychosis may find it less appealing.

“Our results offer preliminary data that the COVID-19 pandemic has affected [Parkinson’s] patients’ access to regular medication,” the researchers concluded.

They added: “COVID-19 has diverted resources away from chronic conditions towards the fight against COVID-19 in many countries. Resource-poor countries seem to be disproportionately affected compared to their affluent counterparts.”

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
Total Posts: 208
Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.
×
Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
Latest Posts
  • SLS-004
  • MJFF webinar, genetics, clinical trials
  • biomarkers, Valted Seq
  • mitochondria

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?